Evidence map›Paper›PMID 40608161›Full record

ArticleDiscover oncology2025

Practical pathological methods for reliable diagnosis of secretory carcinomas of the salivary gland.

Ryo Kawaura, Tomohiko Ishikawa, Hirofumi Shibata, Masashi Kuroki, Kazuhiro Kobayashi, Yuki Hanamatsu, Tatsuhiko Miyazaki, Hiroyuki Tomita, Takuma Ishihara, Hajime Usubuchi and 8 more

Abstract read
In one paragraph

Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Ryo KawauraDepartment of Otolaryngology-Head and Neck Surgery, Gifu University Graduate School of Medicine, 1-1 Yanagido, Gifu, 501-1194, Japan.
Tomohiko IshikawaDepartment of Otolaryngology-Head and Neck Surgery, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai, 980-8575, Miyagi, Japan.
Hirofumi ShibataDepartment of Otolaryngology-Head and Neck Surgery, Gifu University Graduate School of Medicine, 1-1 Yanagido, Gifu, 501-1194, Japan. shibata.hirofumi.b3@f.gifu-u.ac.jp.
Masashi KurokiDepartment of Otolaryngology-Head and Neck Surgery, Gifu University Graduate School of Medicine, 1-1 Yanagido, Gifu, 501-1194, Japan.
Kazuhiro KobayashiDepartment of Tumor Pathology, Gifu University Graduate School of Medicine, 1-1 Yanagido, Gifu, 501-1194, Japan.
Yuki HanamatsuDepartment of Pathology, Gifu University Hospital, 1-1 Yanagido, Gifu, 501- 1194, Japan.
Tatsuhiko MiyazakiDepartment of Pathology, Gifu University Hospital, 1-1 Yanagido, Gifu, 501- 1194, Japan.
Hiroyuki TomitaDepartment of Tumor Pathology, Gifu University Graduate School of Medicine, 1-1 Yanagido, Gifu, 501-1194, Japan.
Takuma IshiharaInnovative and Clinical Research Promotion Center, Gifu University Hospital, 1-1 Yanagido, Gifu, 501-1194, Japan.
Hajime UsubuchiDepartment of Pathology, Sendai Kousei Hospital, 1-20 Tsutsumidori Amamiya-machi, Aoba-ku, Sendai, 981-0914, Miyagi, Japan.
Yayoi AoyamaDepartment of Investigative Pathology, Tohoku University Hospital, 1-1 Seiryo-machi, Aoba-ku, Sendai, 980-8575, Miyagi, Japan.
Yukinori AsadaDepartment of Head and Neck Surgery, Miyagi Cancer Center, 47-1 Medeshima, Natori, 981-1293, Miyagi, Japan.
Takayuki ImaiDepartment of Head and Neck Surgery, Miyagi Cancer Center, 47-1 Medeshima, Natori, 981-1293, Miyagi, Japan.
Akira OhkoshiDepartment of Otolaryngology-Head and Neck Surgery, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai, 980-8575, Miyagi, Japan.
Akira HaraDepartment of Tumor Pathology, Gifu University Graduate School of Medicine, 1-1 Yanagido, Gifu, 501-1194, Japan.
Yukio KatoriDepartment of Otolaryngology-Head and Neck Surgery, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai, 980-8575, Miyagi, Japan.
Toru FurukawaDepartment of Pathology, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai, 980-8575, Miyagi, Japan.
Takenori OgawaDepartment of Otolaryngology-Head and Neck Surgery, Gifu University Graduate School of Medicine, 1-1 Yanagido, Gifu, 501-1194, Japan.

Funding

Japan Society for the Promotion of Science 22K09703Japan Society for the Promotion of Science 24K19767
6 · The paper itself

Abstract

Secretory carcinomas (SCs) of the salivary gland have recently been recognized as low-grade, malignant tumors. Before this designation, most SCs were diagnosed as variants of acinic cell carcinomas (AciCCs). SCs harbor the t(12;15)(p13;q25) translocation that generates an oncogenic fusion gene, ETS variant transcription factor 6/Neurotrophic tyrosine receptor kinase(ETV6::NTRK3). However, detecting fusion genes in a clinical setting is time-consuming and costly. In this study, we examined 31 cases previously diagnosed as AciCC and SC using pathological analyses with detection of fusion genes using ETV6 break-apart fluorescence in-situ hybridization and reverse transcription-polymerase chain reaction. After re-analysis, we found that these 31 cases actually comprised 21 SCs and 10 AciCCs. We examined the diagnostic utility of immunohistochemistry by comparing results with the fusion gene, Pan-Trk, which despite having recently been reported as effective for diagnosis of SC, was not universally accurate. However, combining mammaglobin and S-100 could be particularly useful in diagnosing SC. This practical method will contribute to accurate diagnosis of SCs, while saving time in daily clinical practice.

Indexed as

Acinic cell carcinomaETV6:NTRK3 fusion geneMammaglobinS-100Salivary glandSecretory carcinoma

Identifiers

PMID40608161
PMCPMC12229399

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.